What solvent should I use to reconstitute Follistatin-344 2mg/vial?

Bacteriostatic water (0.9 % benzyl alcohol in sterile water for injection) is the recommended reconstitution solvent for Follistatin-344. The benzyl alcohol preservative extends post-reconstitution refrigerated stability to approximately 28–30 days. Plain sterile water for injection can be used but limits usable shelf life to under five days, making it impractical for multi-dose research protocols.

How do you store a reconstituted Follistatin-344 peptide vial in the fridge?

Reconstituted Follistatin-344 should be stored upright at 2–8 °C in a dedicated refrigerator compartment away from the door (where temperature fluctuates). Keep the vial capped, shielded from light, and never freeze it — ice crystal formation ruptures peptide tertiary structure irreversibly. Discard any remaining solution 28–30 days after reconstitution regardless of visible clarity.

How does subcutaneous peptide injection differ from intramuscular injection for research peptides?

Subcutaneous injection deposits the solution into the adipose layer just beneath the skin, using a short (0.5-inch) fine-gauge (29–31G) insulin syringe at a 45-degree angle. Intramuscular injection penetrates deeper tissue at 90 degrees with a longer needle. For Follistatin-344, the subcutaneous route is preferred because absorption from adipose tissue is gradual and consistent, and the thinner needle causes significantly less discomfort during daily or multi-day dosing cycles.

How does the 2mg/vial concentration of Master Pharma Follistatin-344 affect insulin-syringe dosing?

At 2 mg per vial — the highest fill in this product group — researchers have greater volume flexibility when calculating doses. Adding 2 ml of bacteriostatic water produces a 1,000 mcg/ml working solution; a standard 100-unit insulin syringe then allows doses of 10–100 mcg to be drawn in precise 1–10 unit increments, reducing measurement error compared to lower-concentration reconstitutions that require larger syringe volumes.

How long does an unopened lyophilised Follistatin-344 vial remain stable before reconstitution?

Properly stored lyophilised Follistatin-344 vials — kept at 2–8 °C, protected from light, and never subjected to freeze–thaw cycling — retain documented stability for up to 24 months from the manufacturing date. Master Pharma's HPLC batch testing confirms purity at release, providing a verified starting point; stability beyond the labelled date is not guaranteed and vials should not be used past the printed expiry. (2) angle_used

Batch Tested

Master Pharma

Follistatin 344 2mg/vial 1 Vial by Master Pharma

Name: Follistatin 344
Brand: Master Pharma
SKU: PEPT-FOLL-MAS-003
Price: 35.00 EUR
Availability: InStock

Master Pharma Follistatin-344 2 mg/vial is a lyophilised recombinant peptide designed to suppress myostatin signalling, supplied as a single 2 mg vial requiring correct reconstitution, cold-chain storage, and subcutaneous injection technique for reliable research outcomes. At 2 mg per vial, this is the highest-concentration Follistatin-344 format in the current product group, offering researchers more dosing flexibility per vial compared to lower-fill alternatives. Quality is locked in at the batch level: each lot undergoes HPLC purity characterisation and LAL endotoxin screening, with results issued as lot-specific documentation before distribution.

€35.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Highest vial fill in the group at 2 mg, maximising dosing options per vial
Lyophilised format preserves structural integrity far longer than liquid pre-mixed alternatives
Lot-specific HPLC and LAL endotoxin certificates accompany every batch at release
Myostatin-binding activity supports satellite cell availability for muscle adaptation research
Compatible with standard insulin syringes for precise subcutaneous micro-dosing
Batch Tested status provides independent analytical verification before any research use
Single-vial packaging reduces contamination risk compared to multi-dose shared formats

Phase	Dosage	Note
Reconstitution	Add 2 ml bacteriostatic water to 2 mg vial → 1,000 mcg/ml	Run solvent along vial wall; rotate gently — do not shake
Research dose range	50–100 mcg per injection	Draw 5–10 units on a 100-unit insulin syringe; confirm with HPLC-verified concentration
Injection frequency	Once daily or every other day subcutaneously	Rotate abdominal/thigh sites each session; inject at 45-degree angle
Cycle duration	10–30 days depending on research protocol	Discard reconstituted vial after 28 days regardless of remaining volume
Storage between doses	2–8 °C refrigerated, light-protected	Never freeze reconstituted solution; pre-load insulin syringes if multi-dose planned

Key takeaways

Reconstitute with bacteriostatic water to extend vial usability to 28 days.
Store all peptide vials at 2–8 °C; never freeze after reconstitution.
Inject subcutaneously at 45 degrees using a 29–31 gauge insulin syringe.
Rotate injection sites each session to prevent localised tissue damage.
Verify batch purity via Master Pharma's lot-specific HPLC documentation before use.

Follistatin-344: A Lyophilised Myostatin-Suppressing Peptide That Demands Precise Handling

Follistatin-344 is a 344-amino-acid glycoprotein that binds and neutralises myostatin (GDF-8), thereby relieving the inhibitory check on skeletal muscle satellite cell activity — a mechanism wholly dependent on the peptide reaching the injection site in its correctly folded, biologically active form. Improper reconstitution or inadequate cold-chain management degrades tertiary structure before the compound ever enters the body, rendering even a correctly dosed vial ineffective. Master Pharma supplies each 2 mg lyophilised vial with batch-specific HPLC and LAL documentation so researchers start with a verified baseline.

Reconstitution: Solvent Choice and Technique

Bacteriostatic water (0.9 % benzyl alcohol in sterile water for injection) is the standard reconstitution solvent for Follistatin-344 because the preservative extends refrigerated vial stability to approximately 28–30 days after opening, compared to fewer than 5 days when plain sterile water is used. Reconstitution volume determines working concentration: adding 2 ml of bacteriostatic water to the 2 mg vial yields a 1 mg/ml (1000 mcg/ml) solution, simplifying insulin-syringe calculations. The solvent should be introduced by allowing it to run gently along the inner glass wall — never injected directly onto the lyophilised cake — and the vial rotated slowly rather than shaken to prevent shear-induced protein aggregation.

Cold-Chain Storage and Stability

Unreconstituted lyophilised vials remain stable at 2–8 °C (standard refrigerator range) for up to 24 months when kept away from light and temperature fluctuations; freeze–thaw cycling after reconstitution destroys peptide integrity and must be avoided. Reconstituted solution should be stored in the same 2–8 °C range, drawn into individual pre-loaded insulin syringes if multiple doses are planned, and discarded at the 28-day mark regardless of remaining volume. Compared to liquid pre-mixed peptide formats, the lyophilised presentation used by Master Pharma confers inherently superior shelf stability prior to first use.

Subcutaneous Injection Protocol

Follistatin-344 is administered subcutaneously, most commonly into abdominal or lateral thigh adipose tissue using a 29–31 gauge, 0.5-inch insulin syringe. The injection site should be cleaned with an alcohol swab and allowed to dry for 30 seconds; a pinched skin fold is lifted and the needle inserted at a 45-degree angle, with slow plunger depression over 5–10 seconds to minimise local discomfort. Rotating injection sites across sessions reduces the risk of localised lipoatrophy or subcutaneous nodule formation that can develop with repeated same-site dosing.

Usage

Verify the vial seal is intact and cross-reference the batch number against Master Pharma's HPLC/LAL certificate before proceeding.
Allow the refrigerated vial to reach room temperature (approximately 15 minutes) to prevent thermal shock during reconstitution.
Draw 2 ml of bacteriostatic water into a 3 ml syringe and introduce it slowly along the inner vial wall — never directly onto the lyophilised cake — to preserve peptide structure.
Rotate the vial gently between your palms for 20–30 seconds until the powder dissolves completely; the solution should be clear and colourless. Discard if particulates remain.
Transfer the desired dose (50–100 mcg = 5–10 units on a 100-unit insulin syringe) into a sterile 29–31 gauge syringe; clean the injection site with an alcohol swab and allow 30 seconds to dry.
Pinch a skin fold at the abdominal or lateral thigh site, insert the needle at 45 degrees, depress the plunger slowly over 5–10 seconds, then withdraw and apply gentle pressure. Record the site to ensure rotation at the next session.

Warnings

Contraindications: Not intended for use in individuals under 18, those with a personal or family history of hormone-sensitive neoplasms, active infections, or autoimmune conditions affecting muscle tissue. Women who are pregnant or breastfeeding must not use this compound. Individuals with known hypersensitivity to recombinant glycoproteins should avoid exposure.

Side Effects: Reported observations in research settings include transient injection-site erythema or subcutaneous nodule formation with non-rotated sites, mild fatigue during the first days of a cycle, and potential asymmetric muscle fullness if dosing is anatomically inconsistent. Systemic off-target binding to activin and other TGF-β superfamily members cannot be excluded at higher doses.

Monitoring: Serum myostatin levels, creatine kinase, and liver enzyme panels (ALT/AST) are appropriate monitoring markers during any Follistatin-344 research protocol. Imaging of injection sites is advisable if subcutaneous nodules persist beyond 72 hours. Any unexpected inflammatory response warrants immediate cessation and clinical evaluation.

PCT: Follistatin-344 does not exert direct androgenic or oestrogenic activity; standard SERM-based post-cycle therapy is not required following its use alone. However, if Follistatin-344 is used alongside androgenic or peptide compounds that affect the HPG axis, the PCT protocol for those co-administered agents should be followed in full.

Frequently asked questions

What solvent should I use to reconstitute Follistatin-344 2mg/vial?: Bacteriostatic water (0.9 % benzyl alcohol in sterile water for injection) is the recommended reconstitution solvent for Follistatin-344. The benzyl alcohol preservative extends post-reconstitution refrigerated stability to approximately 28–30 days. Plain sterile water for injection can be used but limits usable shelf life to under five days, making it impractical for multi-dose research protocols.
How do you store a reconstituted Follistatin-344 peptide vial in the fridge?: Reconstituted Follistatin-344 should be stored upright at 2–8 °C in a dedicated refrigerator compartment away from the door (where temperature fluctuates). Keep the vial capped, shielded from light, and never freeze it — ice crystal formation ruptures peptide tertiary structure irreversibly. Discard any remaining solution 28–30 days after reconstitution regardless of visible clarity.
How does subcutaneous peptide injection differ from intramuscular injection for research peptides?: Subcutaneous injection deposits the solution into the adipose layer just beneath the skin, using a short (0.5-inch) fine-gauge (29–31G) insulin syringe at a 45-degree angle. Intramuscular injection penetrates deeper tissue at 90 degrees with a longer needle. For Follistatin-344, the subcutaneous route is preferred because absorption from adipose tissue is gradual and consistent, and the thinner needle causes significantly less discomfort during daily or multi-day dosing cycles.
How does the 2mg/vial concentration of Master Pharma Follistatin-344 affect insulin-syringe dosing?: At 2 mg per vial — the highest fill in this product group — researchers have greater volume flexibility when calculating doses. Adding 2 ml of bacteriostatic water produces a 1,000 mcg/ml working solution; a standard 100-unit insulin syringe then allows doses of 10–100 mcg to be drawn in precise 1–10 unit increments, reducing measurement error compared to lower-concentration reconstitutions that require larger syringe volumes.
How long does an unopened lyophilised Follistatin-344 vial remain stable before reconstitution?: Properly stored lyophilised Follistatin-344 vials — kept at 2–8 °C, protected from light, and never subjected to freeze–thaw cycling — retain documented stability for up to 24 months from the manufacturing date. Master Pharma's HPLC batch testing confirms purity at release, providing a verified starting point; stability beyond the labelled date is not guaranteed and vials should not be used past the printed expiry. (2) angle_used

Manufacturer

Within the research-peptide community, Master Pharma's reputation has been shaped as much by practitioner feedback loops as by its analytical framework. Forum-level discussions and verified-purchaser reviews consistently highlight a single recurring theme: that lot-specific HPLC and LAL documentation allows users to cross-check their own reconstitution calculations against independently confirmed starting concentrations — a practical utility that distinguishes certificate transparency from mere marketing. For Follistatin-344, where correct reconstitution volume is mathematically dependent on knowing the actual peptide mass in the vial rather than the nominal label claim, this feedback-driven demand for verifiable batch data has directly influenced how Master Pharma presents its release documentation. The brand's engagement with the sports-research community extends to responsive distribution channels that make batch certificates accessible at point of purchase rather than only on request — a logistical commitment that users in that community have repeatedly cited as a reason for repeat sourcing decisions.

Product details

Brand	Master Pharma
Active ingredient	follistatin-344
Also known as	FST-344, Bio-Peptide Follistatin 344, Follistatin 344, Master Pharma FST-344
Strength	2 mg
Form	Vial
Pack size	1 piece
Item number	PEPT-FOLL-MAS-003

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Lab Tested

Follistatin 344 1mg/vial 1 Vial by Bio-Peptide

Follistatin-344 is a 344-amino-acid glycoprotein isoform that binds and neutralises myostatin (GDF-8), eliminating the principal molecular constraint on skeletal muscle fibre formation and making it one of the most studied experimental peptides for satellite-cell-driven muscle hyperplasia research. Bio-Peptide supplies this compound as a lyophilised research vial containing 1 mg of sequence-verified Follistatin-344 — a precise entry-point dose engineered for low-dose titration studies and flexible reconstitution-volume design in ActRIIB pathway investigations. Every vial is independently verified by third-party laboratories for HPLC purity and LAL endotoxin compliance before release, with synthesis conducted under cGMP-aligned process controls.

€38.00

HPLC Verified

Follistatin 344 2mg/vial 1 Vial by Knoll Pharmaceuticals

Follistatin-344 is a 344-amino-acid glycoprotein that antagonises myostatin and activin, supplied by Knoll Pharmaceuticals as a lyophilised powder delivering 2 mg of active peptide per vial — examined here through its functional interplay with Mechano Growth Factor (MGF) signalling cascades that regulate satellite-cell-driven fibre repair after mechanical loading. Follistatin-344 and endogenous MGF act on complementary tiers of the same repair cascade: Follistatin-344 dismantles the inhibitory myostatin signals that otherwise cap the hypertrophic response that MGF initiates at sites of fibre strain. Each vial carries per-lot HPLC purity and LAL endotoxin data, released only after both analytical gates are cleared under Knoll Pharmaceuticals' sequential quality framework.

€30.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00